Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohnʼs Disease-Reference-Cited by-同舟云学术

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohnʼs Disease

Published:2017-03 Issue:3 Volume:23 Page:453-460
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Faubion William A.,Dubinsky Marla,Ruemmele Frank M.,Escher Johanna,Rosh Joel,Hyams Jeffrey S.,Eichner Samantha,Li Yao,Reilly Nattanan,Thakkar Roopal B.,Robinson Anne M.,Lazar Andreas

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference30 articles.

1. Rising Incidence of Inflammatory Bowel Disease Among Children: A 12-year Study

2. Mechanisms of growth impairment in pediatric Crohn's disease

3. Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

4. Guidelines for the management of growth failure in childhood inflammatory bowel disease

5. Crohn's disease and growth deficiency in children and adolescents

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study;Pediatric Discovery;2024-06-25

2. Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results;Journal of Pediatric Gastroenterology and Nutrition;2024-05-27

3. Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort;Inflammatory Bowel Diseases;2024-01-08

4. Measurement of Quality of Life in Pediatric Inflammatory Bowel Disease;Pediatric Inflammatory Bowel Disease;2023

5. Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease;Pediatric Inflammatory Bowel Disease;2023